Effects of bazedoxifene in nonflushing postmenopausal women: A randomized phase 2 trial

Menopause

Volumn 18, Issue 5, 2011, Pages 508-514

  Bachmann, Gloria ^a,e   Crosby, Uel ^b   Feldman, Robert A ^c   Ronkin, Sheila ^d   Constantine, Ginger D ^d  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c MIAMI RESEARCH ASSOCIATES   (United States)

^d PFIZER INC   (United States)

^e Clinical Academic Building ^*  (United States)

Author keywords

Bazedoxifene; Hot flushes; Postmenopausal; Selective estrogen receptor modulator; Vasomotor

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BAZEDOXIFENE; CALCIUM CARBONATE; CARBOXY TERMINAL TELOPEPTIDE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOCALCIN; PLACEBO; RALOXIFENE; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; AGED; AMENORRHEA; ARTICLE; ASTHENIA; BONE TURNOVER; BREAST ENGORGEMENT; BRONCHITIS; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; CONTROLLED STUDY; CYST; DEPRESSION; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOMETRIUM; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM THICKNESS; ERUCTATION; FEMALE; FLATULENCE; HEADACHE; HOSTILITY; HOT FLUSH; HUMAN; INFECTION; LEUKORRHEA; MAJOR CLINICAL STUDY; MASTALGIA; MULTICENTER STUDY; NORMAL HUMAN; PERIODONTAL ABSCESS; PHASE 2 CLINICAL TRIAL; PHLEBITIS; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THICKNESS; THROMBOEMBOLISM; TRIACYLGLYCEROL BLOOD LEVEL; URINE INCONTINENCE; VAGINA BLEEDING; VASOMOTOR REFLEX; VERTIGO; VITAL SIGN; VOMITING;

BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; FEMALE; HOT FLASHES; HUMANS; INDOLES; LIPIDS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 79960006736     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181fa358b     Document Type: Article

References (25)

1. Dennison E, Cooper C. Epidemiology of osteoporotic fractures. Horm Res 2000;54:58-63. (Pubitemid 32037589)
2. The North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause 2006;13:340-367.
3. Woolf AD. The global perspective of osteoporosis: the ILAR lecture, June 2004, Berlin. Clin Rheumatol 2006;25:613-618. (Pubitemid 44111300)
4. Fontana A, Delmas PD. Selective estrogen receptors modulators in the prevention and treatment of postmenopausal osteoporosis. Endocrinol Metab Clin North Am 2003;32:219-232. (Pubitemid 36378642)
5. Komm BS, Lyttle CR. Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann N, Acad Sci 2001;949:317-326. (Pubitemid 34059996)
6. Jordan VC. SERMs: meeting the promise of multifunctional medicines. J Natl Cancer Inst 2007;99:350-356. (Pubitemid 47078725)
7. Shelly W, Draper MW, Krishnan V, Wong M, Jaffe RB. Selective estrogen receptor modulators: an update on recent clinical findings. Obstet Gynecol Surv 2008;63:163-181. (Pubitemid 351612435)
8. Lonard DM, Smith CL. Molecular perspectives on selective estrogen receptor modulators (SERMs): progress in understanding their tissuespecific agonist and antagonist actions. Steroids 2002;67:15-24. (Pubitemid 33112000)
9. Arun B, Anthony M, Dunn B. The search for the ideal SERM. Expert Opin Pharmacother 2002;3:681-691. (Pubitemid 34649697)
10. Gennari L, Merlotti D, Valleggi F, Martini G, Nuti R. Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. Drugs Aging 2007;24:361-379. (Pubitemid 46790261)
11. Davies GC, Huster WJ, Lu Y, Plouffe L Jr, Lakshmanan M. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 1999;93:558-565. (Pubitemid 29147076)
12. Goldstein SR. Not all SERMs are created equal. Menopause 2006;13:325-327.
13. McClung MR, Siris E, Cummings S, et al. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. Menopause 2006;13:377-386.
14. Sestak I, Kealy R, Edwards R, Forbes J, Cuzick J. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms. J Clin Oncol 2006;24:3991-3996. (Pubitemid 46630749)
15. Komm BS, Kharode YP, Bodine PV, Harris HA, Miller CP, Lyttle CR. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 2005;146:3999-4008. (Pubitemid 41175771)
16. Miller CP, Collini MD, Tran BD, et al. Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens. J Med Chem 2001;44:1654-1657. (Pubitemid 32852172)
17. Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 2008;23:525-535. (Pubitemid 351501893)
18. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-and activecontrolled clinical trial. J Bone Miner Res 2008;23:1923-1934.
19. Love RR, Cameron L, Connell BL, Leventhal H. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 1991;151:1842-1847.
20. O'Regan RM, Jordan VC. Tamoxifen to raloxifene and beyond. Semin Oncol 2001;28:260-273. (Pubitemid 32554097)
21. Clemett D, Spencer CM. Raloxifene: a review of its use in postmenopausal osteoporosis. Drugs 2000;60:379-411.
22. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637-645. (Pubitemid 29384151)
23. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-137. (Pubitemid 44050394)
24. EVISTA (raloxifene hydrochloride) tablet for oral use [package insert]. Indianapolis, IN: Eli Lilly and Company; 2007.
25. Ronkin S, Northington R, Baracat E, et al. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol 2005;105:1397-1404. (Pubitemid 40734275)